Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Alnylam vs. Ionis: Here's the Better Bad-News Buy

Key PointsAlnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Saturday 10 October →